doi:

DOI: 10.3724/SP.J.1263.2012.00061

Journal of Geriatric Cardiology 2012/9:1 PP.61-67

Diagnosis and management of postural orthostatic tachycardia syndrome: A brief review


Abstract:
Postural orthostatic tachycardia syndrome (POTS) has been recognized since at least 1940. A review of the literature identifies differences in the definition for this condition and wide variations in treatment and outcomes. This syndrome appears to describe a group of conditions with differing pathophysiology, which requires treatment tailored to the true underlying disorder. Patients need to be fully evaluated to guide treatment. Further research is required to effectively classify the range of underlying pathophysiology that can produce this syndrome and to guide optimal management.

Key words:Postural orthostatic tachycardia syndrome,Syncope,tachycardia,Diagnosis,Treatment

ReleaseDate:2014-07-21 16:09:00



1 Carew S, Cooke J, O'Connor M, et al. What is the optimal duration of tilt testing for the assessment of patients with suspected postural tachycardia syndrome? Europace 2009; 11: 635-637.

2 Agarwal AK, Garg R, Ritch A, et al. Postural orthostatic tachycardia syndrome. Postgrad Med J 2007; 83: 478-480.

3 Jacob G, Biaggioni I. Idiopathic orthostatic intolerance and postural tachycardia syndromes. Am J Med Sci 1999; 317: 88-101.

4 Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Auton Neurosci 2011; 161: 46-48.

5 Masuki S, Eisenach JH, Schrage WG, et al. Arterial baroreflex control of heart rate during exercise in postural tachycardia syndrome. J Appl Physiol 2007; 103: 1136-1142.

6 Grubb BP. The postural tachycardia syndrome: A brief review of etiology, diagnosis and treatment. Hellenic J Cardiol 2002; 43: 47-52.

7 Ojha A, McNeeley K, Heller E, et al. Orthostatic syndromes differ in syncope frequency. Am J Med 2010; 123: 245-249.

8 Raj SR. The postural tachycardia syndrome (POTS): pathophysiology, diagnosis & management. Indian Pacing Electrophysiol J 2006; 6: 84-99.

9 Grubb BP, Kanjwal MY, Kosinski DJ. Review: The postural orthostatic tachycardia syndrome: Current concepts in pathophysiology diagnosis and management. J Interv Card Electrophysiol 2001; 5: 9-16.

10 Mathias CJ. Autonomic diseases: Management. J Neurol Neurosurg Psychiatry 2003; 74 (Suppl 3): S42-S47.

11 Low PA, Opfer-Gehrking TL, Textor SC, et al. Postural tachycardia syndrome (POTS). Neurol 1995; 45 (4 Suppl 5): S19-S25.

12 Braune S, Wrocklage C, Schulte-Monting J, et al. Diagnosis of tachycardia syndromes associated with orthostatic symptoms. Clin Auton Res 1999; 9: 97-101.

13 Raj SR, Dzurik MV, Biaggioni I, et al. Diagnosing postural tachycardia syndrome: comparison of tilt versus standing. Circulation 2006; 6: 84-99.

14 Stewart JM, Medow MS, Cherniack NS, et al. Postural hypocapnic hyperventilation is associated with enhanced peripheral vasoconstriction in postural tachycardia syndrome with normal supine blood flow. Am J Physiol Heart Circ Physiol 2006; 291: H904-H913.

15 Lanfranchi PA, Somers VK. Arterial baroreflex function and cardiovascular variability: Interactions and implications. Am J Physiol Regul Integr Comp Physiol 2002; 283; R815-R826.

16 Stewart JM, Munoz J, Weldon A. Clinical and physiological effects of an acute alpha-1 adrenergic agonist and a beta-1 adrenergic antagonist in chronic orthostatic intolerance. Circulation 2002; 106: 2946-2954.

17 Bush VE, Wight VL, Brown CM, et al. Vascular responses to orthostatic stress in patients with postural tachycardia syndrome (POTS), in patients with low orthostatic tolerance, and in asymptomatic controls. Clin Autonom Res 2000; 10: 279-284.

18 Diehl RR. Continuous progression of orthostatic tachycardia as a further feature of the postural tachycardia syndrome. Pacing Clin Electrophysiol 2005; 28: 975-979.

19 Muenter Swift N, Charkoudian N, Dotson RM, et al. Baroreflex control of muscle sympathetic nerve activity in postural orthostatic tachycardia syndrome. Am J Physiol Heart Circ Physiol 2005; 289: H1226-H1233.

20 Garland EM, Winker R, Williams SM, et al. Endothelial NO synthase polymorphisms and postural tachycardia syndrome. Hypertension 2005; 46: 1103-1110.

21 Fu Q, VanGundy TB, Galbreath MM, et al. Cardiac origins of the postural orthostatic tachycardia syndrome. J Am Coll Cardiol 2010; 55: 2858-2868.

22 Peltier AC, Garland E, Raj SR, et al. Distal sudomotor findings in postural tachycardia syndrome. Clin Auton Res 2010; 20: 93-99.

23 Ocon AJ, Medow MS, Taneja I, et al. Decreased upright cerebral blood flow and cerebral autoregulation in normocapnic postural tachycardia syndrome. Am J Physiol Heart Circ Physiol 2009; 297: H664-H673.

24 Agarwal AK, Garg R, Ritch A, et al. Postural orthostatic tachycardia syndrome. Postgrad Med J 2007; 83: 478-480.

25 Raj SR, Biaggioni I, Yamhure PC, et al. Renin-aldosterone paradox and perturbed blood volume regulation underlying postural tachycardia syndrome. Circulation 2005; 111: 1574-1582.

26 Orthostatic intolerance. National Dysautonomia Research Foundation Patient Conference, Minneapolis, Minnesota, USA 2000; Low PA, Ed.

27 Grubb BP, Kanjwal Y, Kosinski DJ. The postural tachycardia syndrome: A concise guide to diagnosis and management. J Cardiovasc Electrophysiol 2006; 17: 108-112.

28 Freitas J, Santos R, Azevedo E, et al. Clinical improvement in patients with orthostatic intolerance after treatment with bisoprolol and fludrocortisone. Clin Auton Res 2000; 10: 293-299.

29 Tremayne V. Proctoclysis: Emergency rectal fluid infusion. Nurs Stand 2009; 24: 46-48.

30 Jacob G, Robertson D, Mosqueda-Garcia R, et al. Hypovolemia in syncope and orthostatic intolerance: Role of the renin-angiotensin system. Am J Med 1997; 103: 128-133.

31 Freitas J, Santos R, Azevedo E, et al. Reversible sympathetic vasomotor dysfunction in POTS patients. Rev Port Cardiol 2000; 19: 1163-1170.

32 Raj SR, Black BK, Biaggioni I, et al. Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome: Less is more. Circulation 2009; 120: 725-734.

33 Lai CC, Fischer PR, Brands CK, et al. Outcomes in adolescents with postural orthostatic tachycardia syndrome treated with midodrine and beta-blockers. Pacing Clin Electrophysiol 2009; 32: 234-238.

34 Gonzalez-Hermosillo JA. Orthostatic intolerance syndromes. Arch Cardiol Mex 2001; 71 (Suppl 1): S58-S62.

35 Haran C. Pressure drop: Treating orthostatic hypotension (Interview with Dr. Blair P. Grubb) 2004. http://www.healthology. com/focus_article.asp (accessed on July 30, 2010).

36 Schondorf R, Freeman R. The importance of orthostatic intolerance in the chronic fatigue syndrome. Am J Med Sci 1999; 317: 117-123.

37 Khan S, Hamid S, Rinaldi C. Treatment of inappropriate sinus tachycardia with ivabradine in a patient with postural orthostatic tachycardia syndrome and a dual chamber pacemaker. Pacing Clin Electrophysiol 2009; 32: 131-133.

38 Hoeldtke RD, Bryner KD, Hoeldtke ME, et al. Treatment of autonomic neuropathy, postural tachycardia and orthostatic syncope with octreotide LAR. Clin Auton Res 2007; 17: 334-340.

39 Hoeldtke RD, Horvath GG, Bryner KD. Treatment of orthostatic tachycardia with erythropoietin. Am J Med 1995; 99: 525-529.

40 Fishbane S, Besarab A. Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol 2007; 2: 1274-1282.

41 Grubb BP. The heterogeneity of symptoms related to dysautonomia. Symposium conducted at the meeting of the National Dysautonomia Research Foundation Northwest Ohio Support Group, Toledo, Ohio, USA, 2002.

42 Kanjwal K, Karabin B, Sheikh M, et al. Pyridostigmine in the treatment of postural orthostatic tachycardia: A single-center experience. Pacing Clin Electrophysiol 2011; 34: 750-755.

43 Filler G, Gow RM, Nadarajaha R, et al. Pharmacokinetics of pyridostigmine in a child with postural tachycardia syndrome. Pediatrics 2006; 118: E1563-E1568.

44 Raj SR, Black BK, Biaggioni I, et al. Acetylcholinesterase inhibition improves tachycardia in postural tachycardia syndrome. Circulation 2005; 111: 2734-2740.

45 Gales BJ, Gales MA. Pyridostigmine in the treatment of orthostatic intolerance. Ann Pharmacother 2007; 41: 314-318.

46 Chen L, Wang L, Sun J, et al. Midodrine hydrochloride is effective in the treatment of children with postural orthostatic tachycardia syndrome. Circ J 2011; 75: 927-931.

47 Grubb BP, McMann MC. The fainting phenomenon: Understanding why people faint and what can be done about it. Futura Publishing Company: New York, USA, 2001.

48 Grubb BP, Kosinski D, Mouhaffel A, et al. The use of methylphenidate in the treatment of refractory neurocardiogenic syncope. Pacing Clin Electrophysiol 1996; 19: 836-840.

49 Kanjwal K, Saeed B, Karabin B, et al. Clinical presentation and management of patients with hyperadrenergic postural orthostatic tachycardia syndrome. A single centre experience. Cardiology 2011; 18: 527-531.

50 Hilz MJ, Marthol H, Neundorfer B. Syncope-a systematic overview of classification, pathogenesis, diagnosis and management. Fortschr Neurol Psychiatr 2002; 70: 95-107.

51 Hain TC. Orthostatic hypotension. Information about dizziness, ataxia and hearing disorders 2001. http://www.tchain.com/ otoneurology/disorders/ (accessed on August 21, 2010).

PDF